x
Disclaimer
This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
is ushering in a new era of brain disorder treatment. BrainsWay is continuously seeking to expand its platform, achieving outcomes not thought possible with traditional medical solutions. Through ongoing investment in R&D and in research initiatives ranging from large-scale multicenter trials to personalized medicine studies, BrainsWay represents the next-generation of treatments for depression and OCD.
Why treat Depression & OCD with BrainsWay Deep TMS?
For
Patients
- FDA-cleared treatment
- Effective, even when medication doesn’t work*
- Short 20-minute sessions
- Non-invasive
- No systemic side effects
- MDD treatment is covered by Medicare and majority of private insurers
Our Treatments
*See response and remission rates in the MDD and OCD treatment pages
For Healthcare
Professionals
- Clinically Proven
- Deeper, Broader Stimulation
- Most robust clinical pipeline
- Financially attractive business model
- Best-in-class customer support
- Provide patients with alternative treatment when medication has proven ineffective
BrainsWay Can Help These Brain Disorders
-
Obsessive Compulsive Disorder (OCD) Treatment
BrainsWay Introduces the First FDA Cleared (De-Novo) Non-invasive Medical Device for the Treatment of OCD.
-
Major Depressive Disorder (MDD) Treatment
Major Depressive Disorder is a neuropsychiatric disorder that is expressed in emotional, physiological and behavioral effects.
BrainsWay By The Numbers
-
500K+
TREATMENTS DELIVERED
-
17
COUNTRIES
-
90%
OF POPULATION IS COVERED BY REIMBURSEMENT
Knowledge Is Power
Regain your confidence and learn more about BrainsWay’s groundbreaking technology.
Read what patients share about their experience
H1-coil Intermittent Theta Burst Stimulation For a Patient With a High Motor Threshold: Case Report
Introduction
Effective H1 coil stimulation for depression requires a dosage of 120% of the resting MT. However, some patients have
Sequential l-PFC, DMPFC-ACC, Accelerated Intermittent Theta Burst DTMS For Highly-Suicidal Treatment-Resistant Depression Patients
Introduction
Depressed, suicidal patients who failed pharmacologic and brain stimulation protocols have significant hopelessness about future treatment, making a four-week
Electric field estimation in deep transcranial magnetic stimulation
Background:
Literature studies [Bersani et al., 2013] showed the ability to treat different neuropsychiatric disorders using the H1 coil. One of